Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization

doi:10.3748/wjg.v27.i13.1330

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4460)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

327

WORD

156

HTML

2365

Figures (1-3)

302

Tables (1-4)

213

Sum=3363

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

322

Download

775

Sum=1097

Apr 7, 2021 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Apr 7, 2021; 27(13): 1330-1340
Published online Apr 7, 2021. doi: 10.3748/wjg.v27.i13.1330

Table 1 Characteristic of the 181 patients

Parameters	Patients, n = 181
Age in yr	52.16 ± 9.73
Sex, men/women	159/22
Cause of liver disease, hepatitis B/C/B and C/others	163/3/1/14
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm	39/86/56
Number of tumors, 1/2/≥ 3	82/12/87
Liver cirrhosis, no/yes	48/133
Ascites, no/small/moderate-massive	91/70/20
CTPV, no/yes	158/23
Invade left and right liver lobes, no/yes	119/62
Type of gross pathology, massive/nodular/diffuse	112/59/10
PVTT type, I/II/III/IV	29/77/68/7
Inferior vena cava tumor thrombus, no/yes	171/10
Arteriovenous fistula, no/yes	125/56
Total bilirubin, µmol/L	17.1 (12.3-24.7)
Prealbumin, mg/L	110 (79-147)
Albumin, g/L	37 ± 4.8
Hemoglobin, g/L	127 (115-142)
WBC, 10⁹/L	5.1 (3.925-6.505)
PLT, 10⁹/L	116 (81- 179.5)
INR	1.12 (1.055-1.205)
PT, S	14.3 (13.7-15.25)
APTT, S	39.5 (37-42.8)
ALT, U/L	46 (31-71.5)
AST, U/L	65 (46-109.5)
GGT, U/L	211 (124.5-352.5)
Cholinesterase, kU/L	4.5 (3.065-5.78)
Creatinine, µmol/L	68 (57.7-78.1)
AFP, µg/L	1210 (82.905-1210)
Child-Pugh grade, A/B/C	123/55/3
ECOG score, 0/1/2/3	8/142/29/2
ALBI grade, 1/2/3	56/120/5
MELD score	7.67 (6.08-9.54)
Overall survival time, mo	4.8 (2.5-8.85)

AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; APTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; CTPV: Cavernous transformation of the portal vein; ECOG: Eastern Cooperative Oncology Group; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; MELD: Model of end-stage liver disease; PLT: Platelets; PVTT: Portal vein tumor thrombosis; WBC: White blood cell.

Table 2 Univariate analysis of survivors vs non-survivors at 3 mo after transarterial chemoembolization

Parameters	Survivors, n = 125	Non-survivors, n = 56	P value
Age in yr	52.56 ± 9.966	51.27 ± 9.212	0.18
Sex, men/women	114/11	45/11	0.04
Cause of liver disease, hepatitis B/C/B and C/others	113/1/0/11	50/2/1/3	0.157
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm	29/57/39	10/29/17	0.659
Number of tumors, 1/2/≥ 3	62/10/53	20/2/34	0.06
Liver cirrhosis, no/yes	36/89	12/44	0.299
Ascites, no/small/moderate-massive	68/47/10	23/23/10	0.087
CTPV, no/yes	110/15	48/8	0.67
Invade left and right liver lobes, no/yes	85/40	34/22	0.34
Type of gross pathology, massive / nodular and diffuse	78/47	34/22	0.829
PVTT type, I/II/III/IV	24/52/44/5	5/25/24/2	0.354
Inferior vena cava tumor thrombus, no/yes	119/6	52/4	0.775
Arteriovenous fistula, no/yes	89/36	36/20	0.352
Total bilirubin, µmol/L	15 (11.15-21.75)	22.25 (17.175-32)	< 0.01
Prealbumin, mg/L	119 (87-159.5)	91.5 (67.25-120.5)	< 0.01
Albumin, g/L	36.407 ± 4.749	37.205 ± 4.853	0.758
Hemoglobin, g/L	127 (115-142)	127 (113.25-143)	0.89
WBC, 10⁹/L	5.06 (4.06-6.27)	5.09 (3.61-6.72)	0.87
PLT, 10⁹/L	119.00 (86.00-180.50)	111.00 (69.25-178.25)	0.15
INR	1.11 (1.06-1.19)	1.12 (1.05-1.26)	0.33
PT, S	14.20 (13.70-15.20)	14.35 (13.70-15.78)	0.38
APTT, S	39.60 (37.25-42.80)	39.35 (36.32-42.85)	0.47
ALT, U/L	41.00 (29.50-62.00)	58.00 (41.25-85.75)	< 0.01
AST, U/L	56.00 (41.00-81.00)	109.00 (72.00-161.75)	< 0.01
GGT, U/L	188.00 (109.00-300.50)	256.00 (186.00-415.25)	< 0.01
Cholinesterase, kU/L	4.88 (3.44-5.84)	3.89 (2.69-5.4675)	0.02
Creatinine, µmol/L	68.60 (58.20-77.25)	66.95 (54.98-79.60)	0.63
AFP, µg/L	1210 (47.86-1210)	1210 (270-1210)	0.34
Child-Pugh grade, A/B/C	94/30/1	29/25/2	< 0.01
ECOG score, 0/1/2/3	8/102/14/1	0/40/15/1	0.016
ALBI grade, 1/2/3	43/79/9	13/41/2	0.31
MELD score	7.53 (5.88-9.02)	9.10 (7.08-11.19)	< 0.01

Table 3 Multivariate analysis of short-term and long-term survival

Variables	Short-term survival		Long-term survival
Variables	OR (95%CI)	P value	OR (95%CI)	P value
Total bilirubin, µmol/L	1.027 (1-1.054)	0.046
AST, U/L	1.014 (1.006-1.021)	P < 0.01
Sex
Men	1
Women	2.832 (1.025-7.828)	0.045
Type of gross pathology
Massive			1
Nodular and diffuse			0.197 (0.075-0.521)	0.001
Number of tumors
1			1
2			1.365 (0.283-6.581)	0.698
3			5.809 (1.563-21.594)	0.009

AST: Aspartate aminotransferase; CI: Confidence interval; OR: Odds ratio.

Table 4 Univariate analysis of survivors vs non-survivors at 12 mo after transarterial chemoembolization

Parameters	Survivors, n = 31	Non-survivors, n = 150	P value
Age in yr	54.770 ± 10.724	51.800 ± 9.400	0.225
Sex, men/women	28/3	131/19	0.871
Cause of liver disease, hepatitis B/C/B and C/others	30/0/0/1	133/3/1/13	0.751
Tumor size, < 5 cm/≥ 5 cm, < 10 cm/≥ 10 cm	11/14/6	28/72/50	0.081
Number of tumors, 1/2/≥ 3	21/4/6	61/8/81	0.002
Liver cirrhosis, no/yes	4/27	44/106	0.059
Ascites, no/small/moderate-massive	16/11/4	75/59/16	0.892
CTPV, no/yes	26/5	132/18	0.74
Invade left and right liver lobes, no/yes	26/5	93/57	0.019
Type of gross pathology, massive/nodular and diffuse	13/18	99/51	0.012
PVTT type, I/II, III/IV	7/10/11/3	22/67/57/4	0.155
Inferior vena cava tumor thrombus, no/yes	30/1	141/9	0.854
Arteriovenous fistula, no/yes	21/10	104/46	0.861
Total bilirubin, µmol/L	19.550 (11.200-33.400)	16.600 (12.900-24.000)	0.436
Prealbumin, mg/L	124.500 (86.750-160.500)	105.000 (78.000-142.000)	0.163
Albumin, g/L	37.047 ± 5.635	36.813 ± 4.622	0.669
Hemoglobin, g/L	132.500 (117.500-146.500)	125.000 (115.000-142.000)	0.316
WBC, 10⁹/L	4.565 (3.398-5.850)	5.100 (4.050-6.610)	0.284
PLT, 10⁹/L	89.000 (63.250-126.000)	119.000 (87.000-182.000)	0.046
INR	1.120 (1.070-1.253)	1.110 (1.050-1.200)	0.281
PT, S	14.400 (13.850-15.875)	14.300 (13.700-15.200)	0.266
APTT, S	39.200 (36.450-42.075)	39.700 (37.100-42.900)	0.541
ALT, U/L	46.500 (38.500-72.000)	45.000 (30.000-72.000)	0.770
AST, U/L	56.500 (41.750-83.750)	71.000 (46.000-115.000)	0.108
GGT, U/L	177.500 (72.250-265.250)	216.000 (132.000-356.000)	0.036
Cholinesterase, kU/L	4.25 (2.775-5.905)	4.51 (3.08-5.79)	0.945
Creatinine, µmol/L	71.300 (61.475-79.500)	67.600 (57.400-78.100)	0.220
AFP, µg/L	568 (15.13~1210)	1210 (97.335-1210)	0.188
Child-Pugh grade, A/B/C	19/11/1	104/44/2	0.373
ECOG score, 0/1/2/3	4/24/3/0	4/118/26/2	0.086
ALBI grade, 1/2/3	13/16/2	43/104/3	0.09
MELD score	7.130 (5.548-9.315)	7.860 (6.070-9.790)	0.348

AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; ALT: Alanine aminotransferase; APTT: Activated partial thromboplastin time; AST: Aspartate aminotransferase; CTPV: Cavernous transformation of the portal vein; ECOG: Eastern Cooperative Oncology Group; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; MELD: Model of end-stage liver disease; PLT: Platelets; PVTT Portal vein tumor thrombosis; WBC: White blood cell.

Citation: Chen KL, Gao J. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization. World J Gastroenterol 2021; 27(13): 1330-1340
URL: https://www.wjgnet.com/1007-9327/full/v27/i13/1330.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i13.1330